EQUITY RESEARCH MEMO

SanBio BV

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)55/100

SanBio BV is a privately held Dutch distributor and manufacturer of life science research and diagnostic products, serving academic, clinical, and industrial laboratories in the BeNeLux region. Founded in 2001, the company supplies reagents, antibodies, and labware from a broad network of third-party suppliers while also producing its own line of MONOSAN antibodies. SanBio positions itself as a knowledge-driven partner, offering technical support and lab services. With a stable niche market presence, the company faces limited growth catalysts typical of the reagent distribution sector, relying on continued regional demand and potential expansion of its own brand. Its long-standing operation and specialized focus provide a reliable, albeit unexciting, investment profile.

Upcoming Catalysts (preview)

  • Q4 2026Launch of new MONOSAN antibody products40% success
  • Q1 2027Expansion of distribution agreements with key suppliers50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)